The company has informed NICE that it will not provide an evidence submission for this appraisal at this time due to ineligibility for the small company fees. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6581
Email enquiries
If you have any queries please email Scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 October 2025 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal at this time due to ineligibility for the small company fees. Therefore, we are suspending the appraisal while we consider the next steps. |
| 02 October 2025 | To appraise the clinical and cost effectiveness of . Tolebrutinib within its marketing authorisation for treating multiple Sclerosis ID6574 |
| 15 April 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual